{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:07:25Z","timestamp":1793362045595,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007787","name":"National Research Centre","doi-asserted-by":"publisher","award":["13010129"],"award-info":[{"award-number":["13010129"]}],"id":[{"id":"10.13039\/100007787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bioorg.2024.107728","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T11:28:00Z","timestamp":1723894080000},"page":"107728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Novel benzenesulfonamides as dual VEGFR2\/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies"],"prefix":"10.1016","volume":"152","author":[{"given":"Rasha M.","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam H.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"El Kerdawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud T.","family":"Abo-Elfadl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman A.Y.","family":"Ghannam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.107728_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154894","article-title":"Anti-breast cancer potential of a new xanthine derivative: In silico, antiproliferative, selectivity, VEGFR-2 inhibition, apoptosis induction and migration inhibition studies","volume":"251","author":"Eissa","year":"2023","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.bioorg.2024.107728_b0010","unstructured":"https:\/\/www.wcrf.org\/cancer-t (Accessed 01 April 2024)."},{"key":"10.1016\/j.bioorg.2024.107728_b0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fmed.2017.00227","article-title":"Tumor heterogeneity in breast cancer","volume":"4","author":"Turashvili","year":"2017","journal-title":"Front Med (lausanne)"},{"key":"10.1016\/j.bioorg.2024.107728_b0020","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bioorg.2024.107728_b0025","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1158\/0008-5472.CAN-06-3316","article-title":"Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain","volume":"67","author":"Palmieri","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bioorg.2024.107728_b0030","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2024.107728_b0035","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ctrv.2014.08.003","article-title":"Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis","volume":"40","author":"Templeton","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bioorg.2024.107728_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.838133","article-title":"Targeting angiogenesis in breast cancer: Current evidence and future perspectives of novel anti-angiogenic approaches","volume":"13","author":"Ayoub","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bioorg.2024.107728_b0045","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/bph.12344","article-title":"Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales","volume":"170","author":"El-Kenawi","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bioorg.2024.107728_b0050","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.1073\/pnas.88.20.9026","article-title":"A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit","volume":"88","author":"Matthews","year":"1991","journal-title":"PNAS"},{"key":"10.1016\/j.bioorg.2024.107728_b0055","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(93)90573-9","article-title":"High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis","volume":"72","author":"Millauer","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2024.107728_b0060","first-page":"1677","article-title":"Identification of a new endothelial cell growth factor receptor tyrosine kinase","volume":"6","author":"Terman","year":"1991","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2024.107728_b0065","first-page":"108","article-title":"Vascular endothelial growth factor receptor-2 in breast cancer","volume":"2010","author":"Guo","year":"1806","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bioorg.2024.107728_b0070","doi-asserted-by":"crossref","first-page":"10797","DOI":"10.1021\/jm301085w","article-title":"Vascular endothelial growth factor (VEGF) receptors: Drugs and new inhibitors","volume":"55","author":"Musumeci","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0075","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/med.21700","article-title":"Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer","volume":"40","author":"Tripathi","year":"2020","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bioorg.2024.107728_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106920","article-title":"Rational design and synthesis of novel quinazolinone N-acetohydrazides as type II multi-kinase inhibitors and potential anticancer agents","volume":"142","author":"Abd El-Karim","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0085","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ncponc0740","article-title":"Drug Insight: VEGF as a therapeutic target for breast cancer","volume":"4","author":"Schneider","year":"2007","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bioorg.2024.107728_b0090","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bioorg.2024.107728_b0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.03.015","article-title":"Targeting the fibroblast growth factor receptor family in cancer","volume":"46","author":"Hallinan","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bioorg.2024.107728_b0100","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bioorg.2024.107728_b0105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13065-024-01135-0","article-title":"Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors","volume":"18","author":"Abdel-Mohsen","year":"2024","journal-title":"BMC Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0110","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/14737140.2018.1491795","article-title":"Future applications of FGF\/FGFR inhibitors in cancer","volume":"18","author":"Ghedini","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.bioorg.2024.107728_b0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.bioorg.2024.107728_b0120","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives","volume":"3","author":"Dieci","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bioorg.2024.107728_b0125","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cytogfr.2021.09.002","article-title":"FGF\/FGFR signaling: From lung development to respiratory diseases","volume":"62","author":"Yang","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.bioorg.2024.107728_b0130","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-19-2035","article-title":"Facts and new hopes on selective FGFR inhibitors in solid tumors","volume":"26","author":"Facchinetti","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bioorg.2024.107728_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115947","article-title":"Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges","volume":"263","author":"Chen","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0140","doi-asserted-by":"crossref","first-page":"e13009","DOI":"10.1111\/cpr.13009","article-title":"Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif"},{"key":"10.1016\/j.bioorg.2024.107728_b0145","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2016.04.036","article-title":"Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects","volume":"377","author":"Li","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bioorg.2024.107728_b0150","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.humpath.2008.06.004","article-title":"High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer","volume":"39","author":"Ghosh","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.bioorg.2024.107728_b0155","doi-asserted-by":"crossref","first-page":"e2100095","DOI":"10.1002\/cbdv.202100095","article-title":"Discovery of 4,6-disubstituted pyrimidine derivatives as novel dual VEGFR2\/FGFR1 inhibitors","volume":"18","author":"Zhang","year":"2021","journal-title":"Chem Biodiversity"},{"key":"10.1016\/j.bioorg.2024.107728_b0160","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/00313020701444549","article-title":"Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells","volume":"39","author":"Shi","year":"2007","journal-title":"Pathology"},{"key":"10.1016\/j.bioorg.2024.107728_b0165","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.1038\/s41388-018-0380-3","article-title":"Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer","volume":"37","author":"Golfmann","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2024.107728_b0170","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bioorg.2024.107728_b0175","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1517\/14656566.2012.679930","article-title":"Sorafenib in liver cancer","volume":"13","author":"Woo","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bioorg.2024.107728_b0180","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/OTT.S189391","article-title":"Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies","volume":"12","author":"Tan","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.bioorg.2024.107728_b0185","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1021\/jm900431g","article-title":"Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)","volume":"52","author":"Roth","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.critrevonc.2014.05.004","article-title":"What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?","volume":"92","author":"Capdevila","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bioorg.2024.107728_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107243","article-title":"Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma","volume":"146","author":"Allam","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.860985","article-title":"Signaling pathway and small-molecule drug discovery of FGFR: A comprehensive review","volume":"10","author":"Zheng","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0205","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/1078-0432.CCR-19-1164","article-title":"Lucitanib for the treatment of HR+\/HER2\u2212 metastatic breast cancer: Results from the multicohort phase II FINESSE study","volume":"26","author":"Hui","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bioorg.2024.107728_b0210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-022-01310-7","article-title":"Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy","volume":"15","author":"Liu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bioorg.2024.107728_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115969","article-title":"Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38\u03b1\/MAPK14 inhibitor","volume":"31","author":"Ali","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0220","doi-asserted-by":"crossref","first-page":"e2200274","DOI":"10.1002\/ardp.202200274","article-title":"Investigation of the carbonic anhydrase inhibitory activity of benzenesulfonamides incorporating substituted fused-pyrimidine tails","volume":"355","author":"Abdel-Mohsen","year":"2022","journal-title":"Arch Pharm (weinheim)"},{"key":"10.1016\/j.bioorg.2024.107728_b0225","doi-asserted-by":"crossref","first-page":"2200434","DOI":"10.1002\/ardp.202200434","article-title":"Novel benzenesulfonamide-thiouracil conjugates with a flexible N-ethyl acetamide linker as selective CA IX and CA XII inhibitors","volume":"356","author":"Abdel-Mohsen","year":"2023","journal-title":"Arch Pharm (weinheim)"},{"key":"10.1016\/j.bioorg.2024.107728_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105424","article-title":"Anticancer profile and anti-inflammatory effect of new N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives","volume":"117","author":"Abdel-Maksoud","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0235","doi-asserted-by":"crossref","first-page":"10491","DOI":"10.3390\/ijms221910491","article-title":"Design, Synthesis and anticancer profile of new 4-(1H-benzo[d]imidazol-1-yl)pyrimidin-2-amine-linked sulfonamide derivatives with V600EBRAF inhibitory effect","volume":"22","author":"Abdel-Maksoud","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bioorg.2024.107728_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106425","article-title":"Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy","volume":"133","author":"Liu","year":"2023","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0245","doi-asserted-by":"crossref","first-page":"42076","DOI":"10.18632\/oncotarget.14942","article-title":"Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2024.107728_b0250","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1158\/1535-7163.MCT-18-0204","article-title":"ODM-203, a selective Inhibitor of FGFR and VEGFR, shows strong antitumor activity, and induces antitumor immunity","volume":"18","author":"Holmstr\u00f6m","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bioorg.2024.107728_b0255","doi-asserted-by":"crossref","first-page":"e001081","DOI":"10.1136\/esmoopen-2020-001081","article-title":"Phase I\/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours","volume":"5","author":"Bono","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.bioorg.2024.107728_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113205","article-title":"Recent advances of dual FGFR inhibitors as a novel therapy for cancer","volume":"214","author":"Liang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116255","article-title":"Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells","volume":"268","author":"Helmy","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0270","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejmech.2011.11.007","article-title":"Synthesis, molecular docking study and antitumor activity of novel 2-phenylindole derivatives","volume":"47","author":"El-Nakkady","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0275","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejmech.2014.03.054","article-title":"Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines","volume":"78","author":"Mojzych","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0280","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/ph16030461","article-title":"Design, synthesis, and biological evaluation of sulfonamide methoxypyridine derivatives as novel PI3K\/mTOR dual inhibitors","volume":"16","author":"Gao","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bioorg.2024.107728_b0285","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejmech.2018.11.061","volume":"163","author":"Eldehna","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105170","article-title":"Discovery of 4-benzyloxy and 4-(2-phenylethoxy) chalcone fibrate hybrids as novel PPARalpha agonists with anti-hyperlipidemic and antioxidant activities: Design, synthesis and in vitro\/in vivo biological evaluation","volume":"115","author":"Hassan","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116279","article-title":"Novel thiazolidin-4-one benzenesulfonamide hybrids as PPAR\u03b3 agonists: Design, synthesis and in vivo anti-diabetic evaluation","volume":"269","author":"Ali","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0300","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bioorg.2024.107728_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105045","article-title":"Design, synthesis and anticancer evaluation of novel 1,3-benzodioxoles and 1,4-benzodioxines","volume":"139","author":"Hassan","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.bioorg.2024.107728_b0310","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10495-008-0300-z","article-title":"Bcl2 family proteins in carcinogenesis and the treatment of cancer","volume":"14","author":"Frenzel","year":"2009","journal-title":"Apoptosis"},{"key":"10.1016\/j.bioorg.2024.107728_b0315","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/CMAR.S154608","article-title":"Bax, Bcl-2, and Bax\/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?","volume":"10","author":"Kulsoom","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.bioorg.2024.107728_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114912","article-title":"Antiproliferative, antiangiogenic and apoptotic effect of new hybrids of quinazoline-4(3H)-ones and sulfachloropyridazine","volume":"245","author":"Zahran","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0325","first-page":"23","article-title":"Wound-healing assay","volume":"294","author":"Rodriguez","year":"2005","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bioorg.2024.107728_b0330","doi-asserted-by":"crossref","first-page":"e2200341","DOI":"10.1002\/ardp.202200341","article-title":"Novel 2-oxo-2-phenylethoxy and benzyloxy diaryl urea hybrids as VEGFR-2 inhibitors: Design, synthesis, and anticancer evaluation","volume":"356","author":"Ghannam","year":"2023","journal-title":"Arch Pharm (weinheim)"},{"key":"10.1016\/j.bioorg.2024.107728_b0335","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.bioorg.2024.107728_b0340","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.str.2014.09.019","article-title":"Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4","volume":"22","author":"Tucker","year":"2014","journal-title":"Structure"},{"key":"10.1016\/j.bioorg.2024.107728_b0345","unstructured":"G. Vignolo, Base dell'ipnoacetina e derivati, Rend Mat Acc Lincei, 6 (1897) 70\u201377."},{"key":"10.1016\/j.bioorg.2024.107728_b0350","unstructured":"Astrazeneca, Patent WO2004\/11410, (2004) A1, Location in patent: 113."},{"key":"10.1016\/j.bioorg.2024.107728_b0355","doi-asserted-by":"crossref","first-page":"15761","DOI":"10.1016\/S0040-4020(97)10013-8","article-title":"Synthesis of 2S-[2-2H]-kynurenine and use in kinetic isotope effect studies with kynureninase","volume":"53","author":"Ross","year":"1997","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2024.107728_b0360","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00706-005-0361-4","article-title":"Solution phase parallel synthesis of 4-aminophenyl ethers using a carboxyl-functionalized ionic liquid as support","volume":"136","author":"Peng","year":"2005","journal-title":"Monatsh Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0365","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.chembiol.2023.01.005","article-title":"Selective and brain-penetrant lanosterol synthase inhibitors target glioma stem-like cells by inducing 24(S),25-epoxycholesterol production","volume":"30","author":"Nguyen","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bioorg.2024.107728_b0370","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1021\/acs.jmedchem.0c01965","article-title":"Discovery of novel small-molecule antiangiogenesis agents to treat diabetic retinopathy","volume":"64","author":"Kim","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105883","article-title":"Design, synthesis and anticancer activity of novel 2-arylbenzimidazole\/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors","volume":"126","author":"Ali","year":"2022","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0380","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bioorg.2024.107728_b0385","first-page":"6528","article-title":"Identification, crystal structure and antitumor activity of fusaric acid from the sugarcane fungal pathogen","volume":"6","author":"Ghannam","year":"2014","journal-title":"Fusarium Sacchari, Int J Pharm Technol"},{"key":"10.1016\/j.bioorg.2024.107728_b0390","doi-asserted-by":"crossref","first-page":"1700299","DOI":"10.1002\/ardp.201700299","article-title":"Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents","volume":"351","author":"Roaiah","year":"2018","journal-title":"Arch Pharm (weinheim)"},{"key":"10.1016\/j.bioorg.2024.107728_b0395","first-page":"1157","article-title":"Imidazo[4,5-b]phenazines as dual topoisomerase I\/II\u03b1 inhibitors: Design synthesis, biological evaluation and molecular docking","volume":"65","author":"Ghannam","year":"2022","journal-title":"Egypt J Chem"},{"key":"10.1016\/j.bioorg.2024.107728_b0400","doi-asserted-by":"crossref","DOI":"10.21608\/ejchem.2024.288226.9691","article-title":"Discovery of novel N-acetylpyrazolines as microtubule inhibitors: Design, synthesis, anticancer evaluation, and molecular docking study","author":"Ali","year":"2024","journal-title":"Egypt J Chem."},{"key":"10.1016\/j.bioorg.2024.107728_b0405","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0304-3835(88)90293-5","article-title":"Use of a tetrazolium based colorimetric assay in assessing photoradiation therapy in vitro","volume":"41","author":"McHale","year":"1988","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bioorg.2024.107728_b0410","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.toxlet.2018.04.008","article-title":"Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells","volume":"291","author":"Allam","year":"2018","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.bioorg.2024.107728_b0415","doi-asserted-by":"crossref","first-page":"11674","DOI":"10.1038\/s41598-018-30046-z","article-title":"Thymoquinone synergizes gemcitabine anti-breast cancer activity via modulating its apoptotic and autophagic activities","volume":"8","author":"Bashmail","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.bioorg.2024.107728_b0420","doi-asserted-by":"crossref","first-page":"13131","DOI":"10.1038\/s41598-017-13357-5","article-title":"Cytotoxicity of thymoquinone alone or in combination with cisplatin (CDDP) against oral squamous cell carcinoma in vitro","volume":"7","author":"Alaufi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bioorg.2024.107728_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121320","article-title":"Enhancement of the antitumor effect of 5-fluorouracil with modulation in drug transporters expression using PI3K inhibitors in colorectal cancer cells","volume":"315","author":"El-Daly","year":"2023","journal-title":"Life Sci"},{"key":"10.1016\/j.bioorg.2024.107728_b0430","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4161\/cam.36224","article-title":"An introduction to the wound healing assay using live-cell microscopy","volume":"8","author":"Jonkman","year":"2014","journal-title":"Cell Adh Migr"},{"key":"10.1016\/j.bioorg.2024.107728_b0435","unstructured":"http:\/\/www.rcsb.org\/."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824006333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824006333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T08:36:04Z","timestamp":1725698164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824006333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":87,"alternative-id":["S0045206824006333"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107728","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel benzenesulfonamides as dual VEGFR2\/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107728","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107728"}}